Answers are grounded in this paper and cite their sources.
The outer membrane of Gram-negative bacteria imposes a formidable barrier to antibacterial agents, severely limiting the efficacy of many novel drug candidates. MGB-BP-3, a DNA minor groove binder, exhibits potent activity against Gram-positive bacteria but has shown limited efficacy against Gram-negative pathogens due to this permeability barrier. The Pandemic Response Box (PRB), a curated library of structurally diverse molecules, provides a resource to identify potential resistance-circumventing compounds that can be repurposed as adjuvants. Here, we screened the PRB for synergy with MGB-BP-3 against Gram-negative priority pathogens. While MGB-BP-3 alone showed minimal in vitro activity, combination testing identified 15 hit compounds, with pafuramidine and sulbactam showing the most synergy against Escherichia coli. To prioritize translatability, we substituted these hits with clinically relevant mechanistic analogues pentamidine and ceftazidime, respectively, which both maintained synergistic activity as measured by Fractional Inhibitory Concentration Indices (FICI < 0.5). Quantitative confocal microscopy using a fluorescent analogue of MGB-BP-3 (S-MGB-245) confirmed that this potentiation was correlated with increased intracellular accumulation of the S-MGB. In vivo efficacy testing using Escherichia coli-infected Galleria mellonella larvae demonstrated significantly improved larval survival with combination therapy compared to monotherapies (p < 0.05). Notably, coadministering subtherapeutic doses of MGB-BP-3 (12.5 mg/kg) with pentamidine (60 mg/kg) or ceftazidime (0.8 mg/kg) achieved ≥75% survival, whereas these exact same concentrations yielded complete mortality when administered individually. These results highlight the potential of clinically used drugs to overcome the intrinsic resistance of Gram-negative bacteria to MGB-BP-3 by compromising the cell envelope, thereby extending the antibacterial spectrum of MGB-BP-3.
No takes yet. Share an insight, caveat, or question.
Eskandari et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: